Close
APE 2026

Sanofi partners with Health2Sync to deliver digital therapeutics in diabetes

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Abbott to Acquire Cancer Test Maker...

In a recent move, Abbott has gone ahead and...

New Policy to Boost Medical Device...

Beijing has gone on to release a new policy...

US Lawmakers Push Access For AI-Powered...

The US bipartisan legislation, which was introduced in the...

Health2Sync, a digital health startup based in Taiwan, specializing in diabetes management, has entered into a partnership with Sanofi, a biopharmaceutical company focused on providing different healthcare solutions including diabetes.

Through this partnership, Health2Sync becomes one of the Sanofi Diabetes Digital Healthcare Ecosystem partners, the two companies aim to apply the digital solution provided by Health2Sync in 300 clinics and hospitals nationwide certified by Taiwan Diabetes Shared Care Network over the next 3 years to improve diabetes care and management locally, as well as to accelerate digital adoption and transformation for clinics and hospitals.

As part of the partnership, Health2Sync will provide patient management software for healthcare professionals and a mobile app for patients in 300 Sanofi-contracted clinics and hospitals, to realize an integrated and digitized diabetes management. The ultimate goal is to improve patients’ understanding of insulin, increase glucose control and raise the insulinization rate in Taiwan. Health2Sync’s analytics platform will assist doctors in real-time with decision making, treatment planning, and generating insights based on the health data collected with patient consent. The solution will help identify patients suited for insulin initiation and facilitate insulin titration for healthcare providers.

“Health2Sync’s solution brings a new definition to the chronic disease care loop, thanks to seamless data collection, real-time analytics, and ultimately, timely medical intervention. With our focus on digital therapeutics, there couldn’t have been a better market than Taiwan as a start, thanks to the local initiatives and robust medical practice. Our commitment to both empower patients and lessen the burden of the cost of complications arising from diabetes will be further exemplified in this partnership,” said Ed Deng, Co-founder & CEO of Health2Sync.

Moving forward, Sanofi and Health2Sync plan to further collaborate in bringing innovative digital therapeutics solutions to patients and healthcare professionals in Taiwan and other markets.

Latest stories

Related stories

Abbott to Acquire Cancer Test Maker for Around $21 Billion

In a recent move, Abbott has gone ahead and...

New Policy to Boost Medical Device Industry in China

Beijing has gone on to release a new policy...

US Lawmakers Push Access For AI-Powered Medical Devices

The US bipartisan legislation, which was introduced in the...

$622m Government Plan for South Korea Medical Device Sector

The South Korea Medical Device Sector is all set...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »